Search
Chikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigationalIn late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.[L48786] There are no approved treatments for active chikungunya virus infection. … [L48731] Chikungunya vaccine (live, attenuated) - marketed under the name Ixchiq - was approved by the FDA in November 2023, becoming the first and only vaccine indicated for the prevention of disease
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigationalMyasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in … agents, notably during the Gulf War.
Products: BRIGADAN-TCinnamaldehyde
go.drugbank.com/drugs/DB14184ApprovedIt occurs naturally in the bark of cinnamon trees and other species of the genus Cinnamomum such as camphor and cassia. Sensitivity to cinnamaldehyde may be identified with a clinical patch test. … Cinnamaldehyde is a naturally occurring flavonoid that gives the spice cinnamon its flavour and odour.
Synonyms: (E)-3-Phenylpropenal, (E)-3-Phenyl-propenalIsavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalResistance to isavuconazole has been associated with the mutation in the target gene CYP51 [FDA Label]. … Following administration, isavuconazonium undergoes biotransformation to form the active moiety, isavuconazole, for the antifungal actions.
Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. … Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group.
Betibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigational[L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia
Cefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational54.6% with the comparator, imipenem/cilastatin. … [A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase
Didanosine
go.drugbank.com/drugs/DB00900ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. … This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains.
Products: BRISTOL VIDEX TABLETAS DE 150 MG, DE LIBERACION RETARDADA X 125 MGEpcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigational[A259736,A258488,A259761,L46516] Epcoritamab promotes the activation and expansion of T-cells and, by being able to bind to both CD20 and CD3, it leads to the T-cell–mediated killing of CD20+ malignant … Epcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells.
Categories: Bispecific CD20-directed CD3 T Cell EngagerBufexamac
go.drugbank.com/drugs/DB13346ApprovedWithdrawnThe use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822]. … Bufexamac was also withdrawn by the EMA in April 2010.